 SAN DIEGO, Sept. 02, 2021 GLOBE NEWSWIRE -- Crinetics Pharmaceuticals, Inc . Nasdaq: CRNX, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Jeff E. Knight as chief operating officer. Mr. Knight will draw on his broad experience in pharmaceutical portfolio strategy, program management, and operations in this newly created role, in which he will be responsible for the strategic management of Crinetics operations and infrastructure including program and portfolio management, alliance management, information technology, and facilities. 